NCT01676753View on ClinicalTrials.gov

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 28, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

February 28, 2022

Conditions
Advanced or Metastatic Breast CancerTriple Negative Breast Cancer
Interventions
DRUG

Dinaciclib

Given IV

DRUG

Pembrolizumab

Given IV

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Jo Chien

OTHER

NCT01676753 - Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer | Biotech Hunter | Biotech Hunter